1. Scrip
  2. >>R&D
  3. >>Clinical Trials

First Efficacy Study for Janssen's Mosaic HIV-1 Preventive Vaccine Starting

 
• By Sten Stovall

Proof-of-concept trialing will soon begin for Janssen's promising HIV-1 prophylactic vaccine, with backing from the Gates Foundation and the NIH.

HIV vaccine
J&J, Gates Foundation and NIH To Test HIV-1 Preventive Vaccine • Source: Shutterstock

Following encouraging trials in monkeys and healthy humans, J&J subsidiary Janssen Pharmaceutical Cos. feels confident enough to enter its investigational mosaic HIV-1 preventive vaccine in proof-of-concept Phase IIb testing, in collaboration with the Gates Foundation and the National Institutes of Health (NIH).

"Based on the immune response in trials with monkeys and subsequently in healthy human volunteers we are optimistic that this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D